You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Aberrant ALK Expression

Showing 1 - 25 of 5,904
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)

Active, not recruiting
  • Melanoma
  • Middletown, New Jersey
  • +3 more
Jan 25, 2022

ALK Phosphorylation Trial in Harbin (crizotinib for rearrangement-negative, high phosphorylated ALK patients)

Completed
  • ALK Phosphorylation
  • crizotinib for rearrangement-negative, high phosphorylated ALK patients
  • Harbin, Heilongjiang, China
    Harbin Medical University Cancer Hospital
Mar 19, 2023

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

Hematologic Malignancies Trial in Assiut (CD56)

Recruiting
  • Hematologic Malignancies
  • CD56
  • Assiut, Egypt
  • +1 more
Jul 20, 2022

Aberrant Gene Expression Prostate Carcinoma

Active, not recruiting
  • Prostate Cancer
    • Burlington, Massachusetts
      Lahey Clinic
    Dec 1, 2021

    Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in

    Completed
    • Follicular Thyroid Cancer
    • Lectin-histochemistry retrospectively performed
    • Singapore, Singapore
      National University Hospital
    Sep 25, 2021

    ALK Fusion Protein Expression, Adjuvant Therapy, NSCLC Trial (Ensatinib, chemo)

    Not yet recruiting
    • ALK Fusion Protein Expression
    • +2 more
    • (no location specified)
    Jan 10, 2022

    Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

    Withdrawn
    • Advanced Malignant Neoplasm
    • +10 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 15, 2022

    Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer

    Not yet recruiting
    • Breast Cancer
    • blood sample collection.
    • (no location specified)
    Jan 21, 2021

    Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

    Active, not recruiting
    • ALK-Positive Anaplastic Large Cell Lymphoma
    • RNAseq
    • Toulouse, France
      IUCT-Oncopole University Hospital
    Jul 3, 2023

    Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function Trial (Acetylcholine, Insulin aspart)

    Not yet recruiting
    • Gestational Diabetes
    • +2 more
    • (no location specified)
    Jul 7, 2023

    Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

    Recruiting
    • Cancer
    • +15 more
    • Data collection and quality of life questionnaire
    • Graz, Austria
    • +40 more
    Jul 27, 2021

    Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

    Recruiting
    • Soft Tissue Sarcoma
    • +2 more
    • Blood and tumor samples
    • Clermont-Ferrand, France
    • +9 more
    Dec 8, 2021

    HER3 Expression in Non-Small Cell Lung Cancer

    Recruiting
    • Non-small Cell Lung Cancer
    • Archival tissue specimen and immunohistochemistry staining
    • Miami, Florida
    • +1 more
    Mar 14, 2023

    Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

    Not yet recruiting
    • Radiotherapy Side Effect
    • +2 more
    • SBRT/SRS/radiation therapy
    • Stockholm, Sweden
      Karolinska University Hospital
    Feb 16, 2023

    Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

    Not yet recruiting
    • Stage IIIB(N2) Non-small Cell Lung Cancer
    • +3 more
    • Pembrolizumab 200 mg IV infusion
    • Beijing, Beijing, China
      Peking University
    May 30, 2023

    NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

    Recruiting
    • NSCLC
    • NK510
    • Tislelizumab，atezolizumab or sugemalimab
    • Nanjing, Jiangsu, China
      General Hospital of Eastern Theater Command
    Oct 23, 2023

    ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)

    Unknown status
    • ALK Gene Rearrangement Positive
    • Non-Squamous Non-Small Cell Neoplasm of Lung
    • Mexico City, Mexico
      Instituto Nacional de Cancerologia
    Feb 8, 2021

    Blepharoptosis, Synkinesis, Hyperkinesis Trial in Hershey (Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating

    Not yet recruiting
    • Blepharoptosis
    • +3 more
    • Oxymetazoline 0.1% (Pf) Oph Soln Ud
    • Preservative free lubricating drops
    • Hershey, Pennsylvania
      M.S. Hershey Medical Center
    Jul 6, 2023

    Non Small Cell Lung Carcinoma NSCLC Trial in Worldwide (Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine +

    Active, not recruiting
    • Non Small Cell Lung Carcinoma NSCLC
    • Durvalumab (MEDI4736)
    • +5 more
    • Anaheim, California
    • +92 more
    Jan 31, 2023

    Neuroblastoma Precision Trial

    Active, not recruiting
    • Neuroblastoma
    • Gene panel sequencing of tumor specimens
    • Los Angeles, California
    • +10 more
    Feb 16, 2022

    Lymphoma, Large B-Cell, Diffuse, Burkitt Lymphoma Trial (Gallium citrate)

    Withdrawn
    • Lymphoma, Large B-Cell, Diffuse
    • Burkitt Lymphoma
    • Gallium citrate
    • (no location specified)
    Oct 8, 2019

    Anaplastic Lymphoma Kinase Gene Translocation, NSCLC Trial in Boston

    Recruiting
    • Anaplastic Lymphoma Kinase Gene Translocation
    • Non-Small Cell Lung Cancer
      • Boston, Massachusetts
        Massachusetts General Hospital Cancer Center
      Jan 14, 2022

      Radiomics for prEdiction of lunG cAncer biologY

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • +3 more
      • PET/CT
      • Poitiers, France
        CHU Poitiers
      Apr 5, 2023

      NSCLC Trial in Guangzhou (TGRX-326)

      Recruiting
      • Non-small Cell Lung Cancer
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jul 18, 2023